- Home
- » Tags
- » Alitretinoin
Top View
- WHO Drug Information Vol
- Retinoids (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tazarotene and Tretinoin) – Update on Teratogenicity and Neuropsychiatric Disorders
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- 1. Benefit Verification and Authorization Support 2. Drug Company Copay Assistance 3
- Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies
- Vitamin a and Its Derivatives- Retinoic Acid and Retinoid Pharmacology
- Inhibitors of the Menin-Mll Interaction Inhibitoren Der Menin-Mll-Interaktion Inhibiteurs De L’Interaction Ménine-Mll
- MAPI Research Trust, Lyon, France
- Oral Alitretinoin for Patients with Refractory Prurigo
- UC Davis Dermatology Online Journal
- Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin and Tazarotene) Œ Update on Teratogenicity and Neuropsychiatric Disorders
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Oncology Agents Not Listed in Seer Book 8
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- A Focused Review of Safety Considerations in Cancer Rehabilitation
- Open-Label Pilot Study of Alitretinoin Gel 0.1% in the Treatment of Photoaging
- A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable Or Metastatic Soft Tissue and Bone Sarcomas in Adults
- Drug-Induced Hyperpigmentation: Review and Case Series
- USP Medicare Model Guidelines V7.0 (With Example Part D Drugs)
- Alitretinoin – Its Use in Intractable Hand Eczema and Other Potential Indications
- Alitretinoin for the Treatment of Chronic Hand Eczema: Clinical Rationale
- Panretin® (Alitretinoin)
- Aminolevulinic Acid and Phototoxicity
- Efficacy of Oral Alitretinoin Versus Oral Cyclosporine a In
- Braf Nras Nf1
- [2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Trifarotene: a Current Review and Perspectives in Dermatology
- NIOSH Alert: Preventing Occupational Exposures to Antineoplastic
- The Detrimental Side Effects of Retinol : Beyond Beauty Products
- An Open Access Database of Licensed Cancer Drugs Pan Pantziarka 1,2, §, Rica Capistrano 1, Arno De Potter 3, Liese Vandeborne 1, Gauthier Bouche 1
- Package Leaflet: Information for the User Alitretinoin Orifarm 10 Mg Capsules, Soft Alitretinoin Orifarm 30 Mg Capsules, Soft Al
- Treating Kaposi Sarcoma If You’Ve Been Diagnosed with Kaposi Sarcoma (KS), Your Treatment Team Will Discuss Your Options with You
- Package Leaflet: Information for the User Toctino 10 Mg Capsules, Soft Toctino 30 Mg Capsules, Soft Alitretinoin WARNING CAN
- Workshop Normal Range
- AIDS-Related Kaposi Sarcoma
- Highlighting the Gaps in Hazard and Risk Assessment of Unregulated
- Supplementary Online Content
- Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin
- Medications That Are Considered Hazardous
- December 2020 List of Off-Patent, Off-Exclusivity Drugs Without An
- Is Alitretinoin (9-Cis-Retinoic Acid) Safe and Effective for Use in Hand Eczema? Jeanne K
- Efficacy and Tolerability of Alitretinoin for Chronic Hand Eczema Under Daily Practice Conditions: Results of the TOCCATA Open Study Comprising 680 Patients
- Retinoid Signals and Th17 Mediated Pathology